Automating MEDITECH Opdivo Prior Authorization Workflows

Klivira streamlines MEDITECH Opdivo prior authorization, accelerating approval times and reducing administrative burden for community hospitals and health systems utilizing MEDITECH Expanse and legacy platforms.

Opdivo (nivolumab) is a high-cost oncology medication frequently requiring prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. Navigating these complex requirements within a MEDITECH environment, which can vary significantly across product lines, presents unique operational challenges for revenue cycle directors and prior authorization coordinators.

Navigating Opdivo PA Across Diverse MEDITECH Environments

The operational landscape for Opdivo prior authorizations in MEDITECH varies based on the specific product line deployed, from modern Expanse to legacy Magic, C/S, and 6.x systems. Klivira’s platform is engineered to adapt to these distinctions, ensuring that order entry for Opdivo, whether via Expanse's Orders activity or older modules, triggers the appropriate ePA workflow. This adaptability is critical for maintaining consistency in PA processes across a health system's varied MEDITECH footprint.

Automated Documentation Retrieval for Opdivo PA from MEDITECH

Successful Opdivo prior authorizations demand comprehensive clinical documentation, including diagnosis codes, prior treatment regimens, and relevant lab results. Klivira integrates with MEDITECH's Expanse via FHIR R4 APIs to retrieve necessary US Core resources from patient summary screens, documentation modules, and problem lists. For legacy MEDITECH deployments, Klivira can leverage established HL7 v2 interfaces (ORM/ORU, MDM) to extract critical data points, ensuring a robust PA packet is assembled without manual chart abstraction.

Optimizing Opdivo's Medical and Pharmacy Benefit PA Workflows

Opdivo often falls under the medical benefit, but its administration and associated medications can involve the pharmacy benefit. Klivira's platform is designed to manage both medical benefit (via X12 278 and Da Vinci PAS) and pharmacy benefit (via NCPDP SCRIPT) prior authorizations. This dual capability ensures that regardless of how Opdivo is covered, the correct electronic prior authorization channel is utilized, minimizing delays and reducing the risk of denials due to incorrect submission pathways.

Klivira's Integration with MEDITECH for Opdivo Workflows

Klivira integrates with MEDITECH Expanse using its Greenfield Workspace, leveraging FHIR R4 APIs and SMART App Launch for seamless clinician experience. This allows for the initiation of prior authorizations directly from the patient context within the EMR and facilitates the write-back of PA status updates. While write-back capabilities for specific resources (e.g., DocumentReference for packet upload, Communication for status) require per-customer verification, Klivira aims to embed PA status directly into MEDITECH's Surveillance/Worklists or Communication/Messaging modules.

Streamlined Specialty Pharmacy Routing for Opdivo

Given Opdivo's status as a specialty medication, efficient routing to specialty pharmacies is paramount. Klivira's platform automates the transmission of approved prior authorizations and associated prescription information to specialty pharmacies, reducing manual handoffs and potential errors. This integration ensures that once an Opdivo PA is approved, the prescription moves swiftly through the fulfillment process, accelerating patient access to treatment.

Frequently asked questions

How does Klivira handle different MEDITECH product lines for Opdivo prior authorization?

Klivira's platform adapts to the specific MEDITECH product line in use. For Expanse, we leverage FHIR R4 APIs and SMART App Launch. For legacy systems like Magic or C/S, we integrate via established HL7 v2 interfaces to ensure comprehensive data exchange and PA workflow initiation for Opdivo.

What clinical data does Klivira extract from MEDITECH to support Opdivo PA requests?

Klivira extracts critical clinical data for Opdivo PAs, including diagnoses, problem lists, medication history, and relevant lab results. This data is pulled from MEDITECH's patient summary, documentation modules, and orders activity, ensuring that all necessary information for payer criteria is included in the prior authorization submission.

Can Klivira manage Opdivo prior authorizations that fall under both medical and pharmacy benefits?

Yes, Klivira's platform is designed to handle both medical benefit and pharmacy benefit prior authorizations for Opdivo. We utilize industry-standard protocols such as X12 278 and Da Vinci PAS for medical benefit and NCPDP SCRIPT for pharmacy benefit submissions, ensuring the correct pathway is used for each specific payer and benefit type.

How does Klivira integrate with specialty pharmacies for Opdivo once a PA is approved?

Upon Opdivo prior authorization approval, Klivira automates the electronic transmission of the approval notification and relevant prescription details directly to the designated specialty pharmacy. This integration streamlines the fulfillment process, reducing manual steps and accelerating the delivery of the medication to the patient.

Does Klivira's integration with MEDITECH support write-back of Opdivo PA status?

Klivira aims to provide write-back capabilities for Opdivo PA status updates directly into MEDITECH, such as within Surveillance/Worklists or Communication/Messaging modules. While FHIR write APIs on Expanse are more limited than read and require per-customer verification, our goal is to ensure clinicians have real-time visibility into prior authorization progress within their EMR.